LRMR Healthcare

Larimar Therapeutics, Inc.

$2.54+7.17%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 263.9M USD
Enterprise value: 114.2M USD
Full-time employees: 71

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #980 of 1,157 fully scored healthcare companies (bottom 16%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 140% from December 2022 to August 2026.
Larimar Therapeutics had 140% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Larimar Therapeutics had 140% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Larimar Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Larimar Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

30/ 100

Oct 5 30 → Nov 4 30

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 177.2% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-65.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-156.5%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-59.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield48.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

8/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-104.4%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-407.5%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-135.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.75

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.36Sector median: 0.6250 · MAD: 0.3380

Current ratio4.70×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.53Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.04×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.90Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Larimar Therapeutics

Is Larimar Therapeutics getting weaker?: Its latest SEC filing (Aug 4, 2026) got weaker in some ways: share count up 177.2%. Its overall score is unchanged at 30/100 since Oct 28, 2026.
How is Larimar Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -65.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -65.4% vs peers 1.5% (weaker than 100% of peers).
Is Larimar Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Larimar Therapeutics?: Less profitable than most of its peers. Profitability scores 8/100 against 1,393 healthcare peers. Return on assets -104.4% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -104.4% vs peers 1.7% (weaker than 100% of peers).
How risky is Larimar Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Mar 31, 2020 · filed Aug 4, 2026 · compared with the quarter ended Dec 31, 2019

Got weaker

Share count up 177.2% (existing holders diluted)

Worth watching: Larimar Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	0 USD	0 USD	—
Net income (12 months)	−45.4M USD	−172.6M USD	+280.1%
Free cash flow (12 months)	−41.5M USD	−156.1M USD	+275.7%
Debt	21.8M USD	20.0M USD	−8.3%
Cash	27.2M USD	92.7M USD	+240.6%
Shares outstanding	37.5M	103.9M	+177.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-64.4%	-28.0%	-38.5%	-40.3%	-113.6%	▼ 73 pts
Return on equity (ROE)	-78.6%	-31.9%	-45.2%	-46.9%	-212.2%	▼ 165 pts
Current ratio	8.16×	11.28×	9.49×	8.02×	2.19×	▼ 73%

LRMR price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #980 of 1,157 fully scored healthcare companies (bottom 16%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 140% from December 2022 to August 2026.

Larimar Therapeutics had 140% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Larimar Therapeutics had 140% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Larimar Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Larimar Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Larimar Therapeutics

Is Larimar Therapeutics getting weaker?

Its latest SEC filing (Aug 4, 2026) got weaker in some ways: share count up 177.2%. Its overall score is unchanged at 30/100 since Oct 28, 2026.

How is Larimar Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -65.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -65.4% vs peers 1.5% (weaker than 100% of peers).

Is Larimar Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Larimar Therapeutics?

Less profitable than most of its peers. Profitability scores 8/100 against 1,393 healthcare peers. Return on assets -104.4% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -104.4% vs peers 1.7% (weaker than 100% of peers).

How risky is Larimar Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

0 USD

0 USD

—

Net income (12 months)

−45.4M USD

−172.6M USD

+280.1%

Free cash flow (12 months)

−41.5M USD

−156.1M USD

+275.7%

Debt

21.8M USD

20.0M USD

−8.3%

Cash

27.2M USD

92.7M USD

+240.6%

Shares outstanding

37.5M

103.9M

+177.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-64.4%

-28.0%

-38.5%

-40.3%

-113.6%

▼ 73 pts

Return on equity (ROE)

-78.6%

-31.9%

-45.2%

-46.9%

-212.2%

▼ 165 pts

Current ratio

8.16×

11.28×

9.49×

8.02×

2.19×

▼ 73%